Paula Sy
Acute Care · Henderson, NVNPI 1871281535
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 98.4% of the total across 302 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 22 manufacturers reported payments, led by AbbVie at 27.0% of the total. Among acute care clinicians in NV with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 302 payments — averaging $17.09 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$1K
- Johnson & Johnson$731
- Sanofi$526
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$408
- Takeda Pharmaceuticals U.S.A., Inc.$326
- Bristol Myers Squibb$273
- plus $2K from 16 others
What the payments were for
- Food & beverage$5,07598%
- Education$852%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 74 | $1,393 |
| Johnson & Johnson | 62 | $731 |
| Sanofi | 27 | $526 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 29 | $408 |
| Takeda Pharmaceuticals U.S.A., Inc. | 15 | $326 |
| Bristol Myers Squibb | 18 | $273 |
| Pfizer | 16 | $262 |
| QOL Medical, LLC | 12 | $256 |
| Lilly USA, LLC | 7 | $179 |
| Regeneron Healthcare Solutions, Inc. | 6 | $120 |
| Merck | 5 | $105 |
| Organon | 8 | $104 |
| Madrigal Pharmaceuticals | 3 | $80 |
| Ironwood Pharmaceuticals, Inc | 4 | $77 |
| Phathom Pharmaceuticals, Inc. | 5 | $76 |
| Redhill Biopharma Inc. | 2 | $53 |
| Ipsen Biopharmaceuticals, Inc | 2 | $52 |
| Aimmune Therapeutics, Inc. | 2 | $40 |
| Gilead | 1 | $33 |
| Celltrion USA Inc. | 2 | $31 |
| Intercept Pharmaceuticals, Inc. | 1 | $19 |
| Braintree Laboratories, Inc. | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$5,160 in reported general payments places this provider in the 95th percentile of 129 acute care providers in Nevada.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Humira(Cf) PenAdalimumab | 12 | $79,233 |
| LinzessLinaclotide | 40 | $31,290 |
| ClenpiqSod Picosulf/Mag Ox/Citric Ac | 57 | $9,808 |
| PlenvuPeg3350/Sod Sul/Nacl/Kcl/Asb/C | 33 | $4,627 |
| SuflavePeg 3350/Sod Sulf,chlr/Pot/Mag | 27 | $3,412 |
| SutabSod Sulf/Pot Chloride/Mag Sulf | 14 | $2,289 |
| Lubiprostone | 11 | $1,007 |
| Gavilyte-GPeg3350/Sod Sulf,bicarb,cl/Kcl | 66 | $962 |
| Omeprazole | 74 | $722 |
| Famotidine | 37 | $279 |
| Gavilyte-CPeg3350/Sod Sulf,bicarb,cl/Kcl | 14 | $242 |
| Pantoprazole Sodium | 32 | $230 |
| Peg-3350 And ElectrolytesPeg3350/Sod Sulf,bicarb,cl/Kcl | 13 | $190 |
| Dicyclomine Hcl | 17 | $188 |
| Ondansetron OdtOndansetron | 16 | $172 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieLinzess | $1,393 | $31,29040 claims |
| Braintree Laboratories, Inc.Suflave, Sutab | $15 | $5,70141 claims |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLCPlenvu | $408 | $4,62733 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 129 acute care providers in Nevada.
Other acute care in Henderson
- Mae NekobaHenderson$8K
- Deanne OmarHenderson$1K
- Nikesha MobleyHenderson$950
- Keith MonsayHenderson$682
- Christina RosatiHenderson$374
- Lindsay BarnesHenderson$323
- Eileen JustoLas Vegas$20K
- Marjeana LampsonCarson City$7K
- Krystal CoffmanLas Vegas$6K
- Frank TalonReno$6K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.